FDA approves Mounjaro, and the tirzepatide pricing clock starts

The Food and Drug Administration approved Eli Lilly's tirzepatide under the brand name Mounjaro for type 2 diabetes in May 2022 ^[3]. The approval launched the first dual GIP and GLP-1 receptor agonist in the US at a list price of about $1,023 for a month's supply, and it started the federal exclusivity clock that blocks generic versions of the molecule ^[1][2].

Tirzepatide is a synthetic analog of the human GIP hormone with a fatty-diacid chain that binds to albumin, giving it a half-life of about five days and allowing once-weekly injection ^[3]. Lilly developed it, and FDA approved it as a first-in-class treatment that lowers blood sugar, improves insulin sensitivity, and in trials reduced body weight by more than 20% ^[3].

What the price looks like

A Peterson-KFF analysis using prices gathered in August 2023 put the US list price of Mounjaro at $1,023 for four pens at the 15 mg dose ^[1]. The same analysis listed $444 in the Netherlands and $319 in Japan for comparable supplies ^[1]. For context, it listed Ozempic (semaglutide) at $936 a month in the US and Wegovy (semaglutide) at $1,349 at the maintenance dose ^[1].

List prices are not what most payers actually pay. Manufacturers give rebates to insurers and coupons to patients, and private insurers and employers may negotiate lower prices ^[1]. The analysis noted that Medicare is not allowed to cover weight-loss drugs under current law and that Medicaid coverage varies by state ^[1]. It also noted that in the UK, Mounjaro was not recommended at the time because of insufficient evidence on effectiveness and cost-effectiveness ^[1].

The exclusivity clock

FDA's Orange Book lists New Chemical Entity exclusivity for tirzepatide expiring 05/13/2027 ^[2]. That five-year window runs from the original approval date and is the main legal barrier to a generic tirzepatide reaching the market. Drug makers who want to challenge the brand's patents typically file at the four-year mark, which industry shorthand calls the NCE-1 date. The Orange Book listing itself shows only the 2027 expiration, not a separate 2026 filing date ^[2].

Patents run well past exclusivity. The Orange Book shows a tirzepatide drug substance and drug product patent expiring 05/13/2036, plus formulation and method-of-use patents running to June and July 2039 ^[2]. Those patents, not the five-year exclusivity, are what would set the practical timeline for copies.

Why it matters for patients

Exclusivity and patents are the reason there is no lawful generic tirzepatide in the US. Lilly has said it is the only lawful supplier of FDA-approved tirzepatide medicines, that Mounjaro and Zepbound are the only FDA-approved tirzepatide products, and that it does not provide the active ingredient to compounding pharmacies, med-spas, wellness centers, or online retailers ^[4]. Anything sold simply as "tirzepatide" was not made, studied, or sold by Lilly and is not FDA-approved ^[4]. Lilly says it has found compounded products containing bacteria, high impurity levels, or a different chemical structure, and in one case nothing but sugar alcohol ^[4].

Price also shapes access. Because coverage and cost sharing vary by plan, the gap between a four-figure list price and what a household pays depends on rebates, coupons and whether a plan covers the drug at all ^[1]. Demand has been enormous regardless: IQVIA reported that Mounjaro and Zepbound are, aside from Harvoni, the only launch products ever to pass $5 billion in sales in their first 12 months, that Mounjaro was selling about $3 billion a month roughly three years after launch, and that 11 million unique patients were using a GLP-1 as of the second quarter of 2025 ^[5].

What happens next

Key dated milestones from FDA's Orange Book listing for tirzepatide: New Product exclusivity expiring 11/08/2026; NCE exclusivity expiring 05/13/2027; labeling-related exclusivity expiring 10/18/2027; and exclusivity tied to obstructive sleep apnea in adults with obesity expiring 12/20/2027 ^[2]. The earliest listed patent expiration is 05/13/2036 ^[2]. Whether any generic applicant files, and when, is not yet known from these sources.